Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (1,081)

Items 401–500 of 1,081

1. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
   Linda S. Steelman, Stephen Lee Abrams, Jarrett T. Whelan, F E Bertrand, D E Ludwig, Jörg Bäsecke, Massimo Libra, Franca Stivala, Michèle Milella, Agostino Tafuri et al. · 2008 · Leukemia
2. Genetic alterations defining NSCLC subtypes and their therapeutic implications
   Pikor, Larissa A., Ramnarine, Varune R., Lam, Stephen, Lam, Wan L. · 2013 · Lung Cancer
3. Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients
   T. Yung, K.C. Allen Chan, Tony S.K. Mok, JOANNA H.M. TONG, Ka‐Fai To, Yuk Ming Dennis Lo · 2009 · Clinical Cancer Research
4. Contemporary radiotherapy: present and future
   Ravi A. Chandra, Florence K. Keane, Francine E.M. Voncken, Charles R. Thomas · 2021 · The Lancet
5. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis
   Thomas J. Giordano, Rork D. Kuick, Dafydd G. Thomas, David E. Misek, Michelle Vinco, Donita Sanders, Zhaowen Zhu, Raffaele Ciampi, Michael H. Roh, Kerby Shedden et al. · 2005 · Oncogene
6. Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers
   Richard M Simon · 2005 · Journal of Clinical Oncology
7. Epidermal Growth Factor Receptor–Targeted Immunoliposomes Significantly Enhance the Efficacy of Multiple Anticancer DrugsIn vivo
   Christoph Mamot, Daryl C. Drummond, Charles O. Noble, V. Kallab, Zexiong Guo, Keelung Hong, Dmitri B. Kirpotin, John W. Park · 2005 · Cancer Research
8. Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
   Yamashita, Taro, Budhu, Anuradha, Forgues, Marshonna, Wang, Xin Wei · 2007 · Cancer Research
9. Clinical pharmacokinetics of tyrosine kinase inhibitors
   van Erp, Nielka P., Gelderblom, Hans, Guchelaar, Henk-Jan · 2009 · Cancer Treatment Reviews
10. One Hundred Years of Lung Cancer
    Stephen G Spiro, Gerard A. Silvestri · 2005 · American Journal of Respiratory and Critical Care Medicine
11. Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity
    Chee‐Keong Toh, Fei Gao, Wan‐Teck Lim, Swan‐Swan Leong, Kam-Weng Fong, Swee‐Peng Yap, Anne Ann Ling Hsu, Philip Eng, Heng‐Nung Koong, Thirugnanam Agasthian et al. · 2006 · Journal of Clinical Oncology
12. Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer
    Lecia Van Dam Sequist, Joachim von Pawel, Edward Graeme Garmey, Wallace Akerley, Wolfram Brugger, Dora Ferrari, Yinpu Chen, Daniel Botelho Costa, David E. Gerber, С. В. Орлов et al. · 2011 · Journal of Clinical Oncology
13. Fast and Sensitive Pretargeted Labeling of Cancer Cells through a Tetrazine/ trans ‐Cyclooctene Cycloaddition
    Neal K. Devaraj, Rabi Upadhyay, Jered B. Haun, Scott A. Hilderbrand, Ralph Weissleder · 2009 · Angewandte Chemie International Edition
14. Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255
    Sean I. Tracy, Toru Mukohara, Mark Hansen, Matthew M. Meyerson, Bruce Evan Johnson, Pasi Antero Janne · 2004 · Cancer Research
15. Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials
    David Michael Jackman, Vincent A. Miller, Leigh‐Anne Cioffredi, Beow Yong Yeap, Pasi Antero Janne, Gregory J. Riely, Marielle I. Gallegos Ruiz, Giuseppe Giaccone, Lecia Van Dam Sequist, Bruce Evan Johnson · 2009 · Clinical Cancer Research
16. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
    Bin-Bing Zhou, Michael Peyton, Biao He, Changnian Liu, Luc Girard, Eian Caudler, Yvonne Y. C. Lo, Frédéric Baribaud, Iwao Mikami, Noemı́ Reguart et al. · 2006 · Cancer Cell
17. Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system
    Simon Gritsch, Tracy T. Batchelor, L. Nicolas Gonzalez Castro · 2021 · Cancer
18. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
    Simon Vyse, Paul H. Huang · 2019 · Signal Transduction and Targeted Therapy
19. Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor–Positive Non–Small-Cell Lung Cancer Patients
    Cappuzzo, Federico, Varella-Garcia, Marileila, Shigematsu, Hisayuki, Domenichini, Irene, Bartolini, Stefania, Ceresoli, Giovanni L., Rossi, Elisa, Ludovini, Vienna, Gregorc, Vanesa, Toschi, Luca et al. · 2005 · Journal of Clinical Oncology
20. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
    Sequist, L.V., Heist, R.S., Shaw, A.T., Fidias, P., Rosovsky, R., Temel, J.S., Lennes, I.T., Digumarthy, S., Waltman, B.A., Bast, E. et al. · 2011 · Annals of Oncology
21. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
    Lucía Regales, Yixuan Gong, Ronglai Shen, Elisa de Stanchina, Igor Vivanco, Aviva J. Goel, Jason A. Koutcher, Maria K. Spassova, Ouathek Ouerfelli, Ingo K. Mellinghoff et al. · 2009 · Journal of Clinical Investigation
22. Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis
    Noriko Motoi, János Szőke, Gregory J. Riely, Venkatraman Seshan, Mark G. Kris, Valerie W. Rusch, William L. Gerald, William David Travis · 2008 · The American Journal of Surgical Pathology
23. Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
    Maruyama, Riichiroh, Nishiwaki, Yutaka, Tamura, Tomohide, Yamamoto, Nobuyuki, Tsuboi, Masahiro, Nakagawa, Kazuhiko, Shinkai, Tetsu, Negoro, Shunichi, Imamura, Fumio, Eguchi, Kenji et al. · 2008 · Journal of Clinical Oncology
24. EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
    Ercan, Dalia, Choi, Hwan Geun, Yun, Cai-Hong, Capelletti, Marzia, Xie, Ting, Eck, Michael J., Gray, Nathanael S., Jänne, Pasi A. · 2015 · Clinical Cancer Research
25. Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer
    Amit Dutt, Alex H. Ramos, Peter S. Hammerman, Craig H. Mermel, Jeonghee Cho, Tanaz Sharifnia, Ajit G. Chande, Kumiko Tanaka, Nicolas Stransky, Heidi E. Greulich et al. · 2011 · PLoS ONE
26. A Glimpse of Structural Biology through X-Ray Crystallography
    Yigong Shi · 2014 · Cell
27. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain
    Jeffrey C. Lee, Igor Vivanco, Rameen Beroukhim, Julie H. Y. Huang, Whei Feng, Ralph M. Debiasi, Koji Yoshimoto, Jennifer C. King, Phioanh Leia Nghiemphu, Yuki Yuza et al. · 2006 · PLoS Medicine
28. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
    Katherine Hastings, Helena Alexandra Yu, Wen Wei, Francisco Sánchez-Vega, Michelle DeVeaux, Jungmin Choi, Hira A. Rizvi, Aaron Elliott Lisberg, Anna Truini, Christine Lydon et al. · 2019 · Annals of Oncology
29. Molecular Mechanisms of Epidermal Growth Factor Receptor (EGFR) Activation and Response to Gefitinib and Other EGFR-Targeting Drugs
    Mayumi Ono, Michihiko Kuwano · 2006 · Clinical Cancer Research
30. EGFR signaling pathway as therapeutic target in human cancers
    Elena Levantini, Giorgia Maroni, Marzia Del Re, Daniel Geoffrey Tenen · 2022 · Seminars in Cancer Biology
31. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond
    Marc Ladanyi, William J. Pao · 2008 · Modern Pathology
32. Functional precision cancer medicine—moving beyond pure genomics
    Letai, Anthony · 2017 · Nature Medicine
33. Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies
    Neil L. Spector, Wenle Xia, Howard A. Burris, Herbert I. Hurwitz, E. Claire Dees, Afshin Dowlati, Bert H. O’Neil, Beth A. Overmoyer, Paul Kelly Marcom, Kimberly Blackwell et al. · 2005 · Journal of Clinical Oncology
34. Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
    Masahiko Ando, Isamu Okamoto, Nobuyuki Yamamoto, Koji Takeda, Kenji Tamura, Takashi Seto, Yutaka Ariyoshi, Masahiro Fukuoka · 2006 · Journal of Clinical Oncology
35. Successes and failures of the teachable moment
    Ellen R. Gritz, Michelle Cororve Fingeret, Damon J. Vidrine, Amy B. Lazev, Netri V. Mehta, Gregory P. Reece · 2005 · Cancer
36. Molecular biology of lung cancer.
    Wendy A. Cooper, David Chi-Leung Lam, Sandra A O'Toole, John Dorrance Minna · 2013 · Europe PMC (PubMed Central)
37. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing
    Roman Kurt Thomas, Elizabeth Nickerson, Jan Fredrik Simons, Pasi Antero Janne, Torstein Tengs, Yuki Yuza, Levi A. Garraway, Thomas LaFramboise, Jeffrey C. Lee, Kinjal Shah et al. · 2006 · Nature Medicine
38. Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer
    Federico Cappuzzo, Elisabetta Magrini, Giovanni Luca Ceresoli, Stefania Bartolini, Elisa Rossi, V. Ludovini, Vanesa Gregorc, C. Ligorio, Alessandra Cancellieri, Stefania Damiani et al. · 2004 · JNCI Journal of the National Cancer Institute
39. Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
    Yibing Shan, Michael P. Eastwood, Xuewu Zhang, Eric T. Kim, Anton S. Arkhipov, Ron O. Dror, John Jumper, John Kuriyan, David Elliot Shaw · 2012 · Cell
40. Lineage dependency and lineage-survival oncogenes in human cancer
    Levi A. Garraway, William R. Sellers · 2006 · Nature reviews. Cancer
41. Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
    Gregory J. Riely, Katerina A. Politi, Vincent A. Miller, William J. Pao · 2006 · Clinical Cancer Research
42. Gene expression profiling of human sarcomas: insights into sarcoma biology.
    Baird, Kristin, Davis, Sean, Antonescu, Cristina R., Harper, Ursula L., Walker, Robert L., Chen, Yidong, Glatfelter, Arthur A., Duray, Paul H., Meltzer, Paul S. · 2005 · Cancer Research
43. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
    Zhang, Xuewu, Pickin, Kerry A., Bose, Ron, Jura, Natalia, Cole, Philip A., Kuriyan, John · 2007 · Nature
44. Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
    Jessica J. Lin, Stephanie Cardarella, Christine Lydon, Suzanne Eleanor Dahlberg, David Michael Jackman, Pasi Antero Janne, Bruce Evan Johnson · 2015 · Journal of Thoracic Oncology
45. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
    Tae Kon Kim, Esten N. Vandsemb, Roy S. Herbst, Lieping Chen · 2022 · Nature Reviews Drug Discovery
46. Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
    Glenwood D. Goss, Chris J. O’Callaghan, Ian A. J. Lorimer, Ming‐Sound Tsao, Gregory A. Masters, James R. Jett, Martin Joseph Edelman, Rogério Lilenbaum, Hak Choy, Fadlo Raja Khuri et al. · 2013 · Journal of Clinical Oncology
47. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations
    Rohit Bhargava, William L. Gerald, Allan R. Li, Qiulu Pan, Priti Lal, Marc Ladanyi, Beiyun Chen · 2005 · Modern Pathology
48. Expression Profile–Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors
    Toshiyuki Takeuchi, Shuta Tomida, Yasushi Yatabe, Takayuki Kosaka, Hirotaka Osada, Kiyoshi Yanagisawa, Tetsuya Mitsudomi, Takashi Takahashi · 2006 · Journal of Clinical Oncology
49. Gold nanoparticles: From nanomedicine to nanosensing
    Adegboyega K. Oyelere · 2008 · Nanotechnology Science and Applications
50. Clinical Applications for microRNAs in Cancer
    Serge Patrick Nana-Sinkam, Carlo Maria Croce · 2012 · Clinical Pharmacology & Therapeutics
51. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression
    Xiangming Ji, Jun Qian, S.M. Jamshedur Rahman, Peter J. Siska, Yong Zou, Bradford K. Harris, Megan D. Hoeksema, Irina A. Trenary, Heidi Chen, Rosana Eisenberg et al. · 2018 · Oncogene
52. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
    Ciric To, Jaebong Jang, Ting Chen, Eunyoung Park, Mierzhati Mushajiang, Dries J.H. De Clercq, Man Xu, Stephen Wang, Michael D. Cameron, David E. Heppner et al. · 2019 · Cancer Discovery
53. Non–Small Cell Lung Cancer
    David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas Anthony D’Amico, Todd L. Demmy, Apar Kishor Ganti, Ramaswamy Govindan et al. · 2012 · Journal of the National Comprehensive Cancer Network
54. Prognostic versus predictive value of biomarkers in oncology
    Corina N.A.M. Oldenhuis, Sjoukje F. Oosting, Jourik A. Gietema, Elisabeth G.E. de Vries · 2008 · European Journal of Cancer
55. “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., Lassman, A. B. · 2011 · Neuro-Oncology
56. Central Nervous System Tumors
    Jan C. Buckner, Paul D. Brown, Brian Patrick O’Neill, Fredric Bruce Meyer, Cynthia Wetmore, Joon H. Uhm · 2007 · Mayo Clinic Proceedings
57. Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
    George N. Naumov, Monique B. Nilsson, Tina Cascone, Alexandra Briggs, Oddbjørn Straume, Lars A. Akslen, Eugene Lifshits, Lauren A. Byers, Li Xu, Hua-Kang Wu et al. · 2009 · Clinical Cancer Research
58. Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
    Justin F. Gainor, Alice Tsang Shaw · 2013 · Journal of Clinical Oncology
59. Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions
    Justin F. Gainor, Alice Tsang Shaw · 2013 · The Oncologist
60. Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection
    Huang, Fei, Reeves, Karen, Han, Xia, Fairchild, Craig, Platero, Suso, Wong, Tai W., Lee, Francis, Shaw, Peter, Clark, Edwin · 2007 · Cancer Research
61. Drug-sensitive FGFR2 mutations in endometrial carcinoma
    Amit Dutt, Helga Birgitte Salvesen, Tzu-Hsiu Chen, Alex H. Ramos, Robert C. Onofrio, Charlie Hatton, Richard Nicoletti, Wendy Winckler, Rupinder Grewal, Megan Hanna et al. · 2008 · Proceedings of the National Academy of Sciences
62. Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
    Igor Vivanco, H. Ian Robins, Daniel Rohle, Carl Campos, Christian Grommes, Phioanh Leia Nghiemphu, Sara Kubek, Barbara Oldrini, Milan G. Chheda, Nicolas A. Yannuzzi et al. · 2012 · Cancer Discovery
63. Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics
    Mark Steven Cragg, Junya Kuroda, Hamsa Puthalakath, David C.S. Huang, Andreas Strasser · 2007 · PLoS Medicine
64. Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
    Xiuning Le, Monique B. Nilsson, Jonathan Wade Goldman, Martin Reck, Kazuhiko Nakagawa, T. Kato, Luis Paz Ares, Bente Frimodt‐Moller, Katharina Wolff, Carla Visseren‐Grul et al. · 2020 · Journal of Thoracic Oncology
65. Current Management of Gallbladder Carcinoma
    Andrew Xiuxuan Zhu, Theodore Sunki Hong, Aram F. Hezel, David A. Kooby · 2010 · The Oncologist
66. EGFR Mutation and Resistance of Non-Small-Cell Lung Cancer to Gefitinib
    Nasser H. Hanna · 2006 · Yearbook of Oncology
67. The epidermal growth factor receptor: from development to tumorigenesis
    Maria Chiara Sibilia, Renate Kroismayr, Beate M. Lichtenberger, Anuradha Natarajan, Manfred Hecking, Martin Holcmann · 2007 · Differentiation
68. Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
    Helena Alexandra Yu, Camelia S. Sima, James Guoxian Huang, Stephen Barnett Solomon, Andreas Rimner, Paul K. Paik, Maria Catherine Pietanza, Christopher G. Azzoli, Naiyer A. Rizvi, Lee M. Krug et al. · 2013 · Journal of Thoracic Oncology
69. A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
    Gabriele Schaefer, Lauric Haber, Lisa Crocker, Steven Shia, Lily Shao, Donald J. Dowbenko, Klára Tótpál, Anne Wong, Chingwei V. Lee, Scott S. Stawicki et al. · 2011 · Cancer Cell
70. Cancer Survivorship—Genetic Susceptibility and Second Primary Cancers: Research Strategies and Recommendations
    Lois B. Travis, Charles S. Rabkin, Línda Morris Brown, James M. Allan, Blanche P. Alter, Christine B. Ambrosone, Colin B. Begg, Neil E. Caporaso, Stephen Jacob Chanock, Angela M. DeMichele et al. · 2006 · JNCI Journal of the National Cancer Institute
71. Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management
    Thomas James Lynch, Ed S. Kim, Beth Eaby, Jody S. Garey, Dennis Paul West, Mario E. Lacouture · 2007 · The Oncologist
72. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
    Zhao, Ben, Wang, Lu, Qiu, Hong, Zhang, Mingsheng, Sun, Li, Peng, Ping, Yu, Qianqian, Yuan, Xianglin · 2017 · Oncotarget
73. Disrupting insulin-like growth factor signaling as a potential cancer therapy
    Deepali Sachdev, Douglas Yee · 2007 · Molecular Cancer Therapeutics
74. Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis
    Xiaojun Zhao, Barbara A. Weir, Thomas LaFramboise, Ming Gang Lin, Rameen Beroukhim, Levi A. Garraway, Javad Beheshti, Jeffrey C. Lee, Katsuhiko Naoki, William G. Richards et al. · 2005 · Cancer Research
75. Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib
    Floriana Morgillo, Jong Kyu Woo, Edward S. Kim, Waun Ki Hong, Ho‐Young Lee · 2006 · Cancer Research
76. Personalized medicine in oncology: the future is now
    Richard L. Schilsky · 2010 · Nature Reviews Drug Discovery
77. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advancedEGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study
    Shi, Y.K., Wang, L., Han, B.H., Li, W., Yu, P., Liu, Y.P., Ding, C.M., Song, X., Ma, Z.Y., Ren, X.L. et al. · 2017 · Annals of Oncology
78. Making sense of cancer genomic data
    Lynda Chin, William C. Hahn, Gad A. Getz, Matthew M. Meyerson · 2011 · Genes & Development
79. Illuminating the dark phosphoproteome
    Elise J. Needham, Benjamin L. Parker, Timur Burykin, David Ernest James, Sean J. Humphrey · 2019 · Science Signaling
80. Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas
    Miguel Tarón, Yukito Ichinose, Rafael Rosell, Tony S.K. Mok, Bartomeu Massutí, Lurdes Zamora, José Luís Mate, Christian Manegold, Mayumi Ono, Cristina Queralt et al. · 2005 · Clinical Cancer Research
81. Strategies to overcome resistance to targeted protein kinase inhibitors
    Henrik Daub, Katja Specht, Axel Ullrich · 2004 · Nature Reviews Drug Discovery
82. Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases
    Yihua Sun, Yan Ren, Zhaoyuan Fang, Chenguang Li, Rong Fang, Bin Gao, Xiangkun Han, Weidong Tian, William J. Pao, Haiquan Chen et al. · 2010 · Journal of Clinical Oncology
83. RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer
    Gerold Bepler, Irina Kusmartseva, Swati Sharma, Ashish Gautam, Alan B Cantor, Anupama Sharma, George R. Simon · 2006 · Journal of Clinical Oncology
84. Dasatinib (BMS-354825) Tyrosine Kinase Inhibitor Suppresses Invasion and Induces Cell Cycle Arrest and Apoptosis of Head and Neck Squamous Cell Carcinoma and Non–Small Cell Lung Cancer Cells
    Faye M. Johnson, Babita Saigal, Moshe Talpaz, Nicholas J. Donato · 2005 · Clinical Cancer Research
85. Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
    Recondo, Gonzalo, Facchinetti, Francesco, Olaussen, Ken A., Besse, Benjamin, Friboulet, Luc · 2018 · Nature Reviews Clinical Oncology
86. Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease
    Jianchun Chen, Fenghua Zeng, Steven J. Forrester, Satoru Eguchi, Ming‐Zhi Zhang, Raymond Clement Harris · 2016 · Physiological Reviews
87. Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
    Nilofer Saba Azad, Edwin M. Posadas, Virginia E. Kwitkowski, Seth M. Steinberg, Lokesh Jain, Christina M. Annunziata, Lori M. Minasian, Gisele Sarosy, Herbert L. Kotz, Ahalya Premkumar et al. · 2008 · Journal of Clinical Oncology
88. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
    David A. Reardon, Merrill J. Egorin, Jennifer A. Quinn, Jeremy N. Rich, Idharan Gururangan, James J. Vredenburgh, Annick Desjardins, Sith Sathornsumetee, James M. Provenzale, James E. Herndon et al. · 2005 · Journal of Clinical Oncology
89. Emerging molecular biomarkers—blood-based strategies to detect and monitor cancer
    Samir Hanash, Christina S. Baik, Olli Kallioniemi · 2011 · Nature Reviews Clinical Oncology
90. A perspective on anti-EGFR therapies targeting triple-negative breast cancer.
    Katsuya Nakai, Mien‐Chie Hung, Hirohito Yamaguchi · 2016 · Europe PMC (PubMed Central)
91. Molecularly targeted therapy for malignant glioma
    Sith Sathornsumetee, David A. Reardon, Annick Desjardins, Jennifer A. Quinn, James J. Vredenburgh, Jeremy N. Rich · 2007 · Cancer
92. Evaluating the Efficiency of Targeted Designs for Randomized Clinical Trials
    Richard M Simon, Aboubakar Maitournam · 2004 · Clinical Cancer Research
93. Molecular chess? Hallmarks of anti-cancer drug resistance
    Ian A. Cree, Peter Charlton · 2017 · BMC Cancer
94. Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
    Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I. et al. · 2014 · Annals of Oncology
95. Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer
    Hideharu Kimura, Kazuo Kasahara, Makoto Kawaishi, Hideo Kunitoh, Tomohide Tamura, Brian R. Holloway, Kazuto Nishio · 2006 · Clinical Cancer Research
96. Refining the treatment of NSCLC according to histological and molecular subtypes
    Anish Thomas, Stephen V. Liu, Deepa Suresh Subramaniam, Giuseppe Giaccone · 2015 · Nature Reviews Clinical Oncology
97. Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
    Yixuan Gong, Romel Somwar, Katerina A. Politi, Marissa N. Balak, Juliann Chmielecki, Xuejun Jiang, William J. Pao · 2007 · PLoS Medicine
98. Pharmacogenomics: bench to bedside
    Richard M. Weinshilboum, Liewei Wang · 2004 · Nature Reviews Drug Discovery
99. Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response
    Wu, Jenn-Yu, Wu, Shang-Gin, Yang, Chih-Hsin, Gow, Chien-Hung, Chang, Yih-Leong, Yu, Chong-Jen, Shih, Jin-Yuan, Yang, Pan-Chyr · 2008 · Clinical Cancer Research
100. EML4-ALK: Honing In on a New Target in Non–Small-Cell Lung Cancer
     Leora Horn, William J. Pao · 2009 · Journal of Clinical Oncology